Pharmacovigilance (PV) Market By Trial Phase, Service Provider, Type and End User - Global Industry Analysis and Forecast to 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 100 Pages

Description

Industry Outlook and Trend Analysis

The Pharmacovigilance (PV) Market was worth USD 2.78 billion in 2014 and is expected to reach approximately USD 8.46 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 13.14% during the forecast period. Expanding rate of Adverse Drug Reactions (ADRs) is anticipated to quicken the interest for pharmacovigilance services over the conjecture time frame. Developing prevalence of chronic diseases is another significant benefactor for the PV development. Treatment of these chronic diseases require uptake of blend of medications bringing about ADR. To curtail this issue, PV administrations are used. Also, presence of charitable association for spreading the awareness associated with PV, for example, International Society of Pharmacovigilance (ISoP) is anticipated to encourage the selection of PV amid the conjecture time frame as it is concentrating on upgrading safe and appropriate use of medications at worldwide level. Increasing government activities relating to adoption of PV administrations is foreseen to impel the business development in the following years.

Clinical Trial Phase Outlook and Trend Analysis

The Phase IV (Post marketing) clinical trial section ruled the market in 2016. PV arrangements function as an extra security measure for the drug undergoing clinical trials. Stage IV is fundamental phase of whole clinical trials as unsuspected unfavourable medication responses can be recognized in this stage. Consequently, the information gathered and surveyed amid this stage is anticipated to be of the most elevated significance. The Phase III section is foreseen to witness lucrative development.

Service Provider Outlook and Trend Analysis

Contract outsourcing held the prevailing share in 2016 and is anticipated to witness quickest developing fragment in the following years. It is because of the advantages related with outsourcing such as resource flexibility, risk mitigation, reduction in fixed cost, and reduction of upfront investments. Contract outsourcing associations give arrangements, for example, process plan Standard Operating Procedure (SOP), PV audits, and other customized services.

Type Outlook and Trend Analysis

Spontaneous reporting captured the biggest share of the pharmacovigilance market in 2016, attributable to wide usage in location of new, genuine and uncommon ADRs and serves as a proficient and economical technique. Wide use of surveillance reports created through this technique by pharmaceutical organizations and regulatory authorities is likewise in charge of capitalizing the share of the overall industry of spontaneous reporting. Cohort event monitoring (CEM) is anticipated to be the quickest developing fragment inferable from its expanding application in discovery of extensive variety of unfavourable clinical events.

End User outlook and Trend Analysis

In 2016, hospitals represented the biggest revenue share of the pharmacovigilance market based on end use. Hospitals serves columnist associations, which report the ADRs, happened amid a specific time period, to administrative experts keeping in mind the end goal to find out the requirement for post marketing surveillance. Rising frequency of ADRs and medication errors are anticipated to drive the hospital section development over the gauge time frame.

Regional Outlook and Trend Analysis

North America captured the biggest revenue share in 2016, attributable to presence of key pharmaceutical and medicinal devices players in this area, adding to the general income in this area. Rising level of drug abuse and related unfavourable drug reactions is a main source of death and morbidity. The previously mentioned components are high development rendering factors for the pharmacovigilance market in North America. Asia Pacific is anticipated to develop at lucrative rate, owing to accessibility of expansive number of outsourcing associations.

Competitive Insights

The leading players in the market are BioClinica, LabCorp, Capgemini, Clinquest Group B.V, iMEDGlobal, ITClinical, Cognizant, ArisGlobal LLC, ICON plc, IBM and Accenture. This industry is witnessing a tremendous boost due to patent expiration of branded drugs and rising number of new drug developments. This has encouraged several local and international pharmacovigilance service providers in the market.

The Pharmacovigilance (PV) Market is segmented as follows-

By Clinical Trial Phase:


Pre-clinical
Phase I
Phase II
Phase III
Phase IV


By Service Provider:


In-house
Contract Outsourcing


By Type:


Intensified ADR Reporting
Targeted Spontaneous Reporting
Spontaneous Reporting
EHR Mining
Cohort Event Monitoring


By End User:


Research Organizations
Hospitals
Industrial


By Region


North America


U.S.
Canada
Mexico


Europe

Germany
UK
France
Russia
Italy
Rest of Europe


Asia-Pacific

China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific


South America

Brazil
Argentina
Columbia
South Africa
Rest of South America


Middle East and Africa

Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA




Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023`
What will be the industry market growth from 2015 to 2023`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increasing Incidence Rates of ADR and Drug Toxicity
3.2.1.2. Growing Drug Consumption and Drug Development Rates
3.2.2. Restraints
3.2.2.1. Lack of Skilled Labor
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2014-2023)
4.1.2. Canada Market States and Outlook (2014-2023)
4.1.3. Mexico Market States and Outlook (2014-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2014-2023)
4.2.2. France Market States and Outlook (2014-2023)
4.2.3. UK Market States and Outlook (2014-2023)
4.2.4. Russia Market States and Outlook (2014-2023)
4.2.5. Italy Market States and Outlook (2014-2023)
4.2.6. Rest of Europe Market States and Outlook (2014-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2014-2023)
4.3.2. Japan Market States and Outlook (2014-2023)
4.3.3. Korea Market States and Outlook (2014-2023)
4.3.4. India Market States and Outlook (2014-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2014-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2014-2023)
4.4.2. Argentina Market States and Outlook (2014-2023)
4.4.3. Columbia Market States and Outlook (2014-2023)
4.4.4. Rest of South America Market States and Outlook (2014-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2014-2023)
4.5.2. UAE Market States and Outlook (2014-2023)
4.5.3. Egypt Market States and Outlook (2014-2023)
4.5.4. Nigeria Market States and Outlook (2014-2023)
4.5.5. South Africa Market States and Outlook (2014-2023)
4.5.6. Rest of MEA Market States and Outlook (2014-2023)
5. Pharmacovigilance (PV) Market, By Trial Phase
5.1. Introduction
5.2. Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Trial Phase (2014-2018)
5.2.1. Global Pharmacovigilance (PV) Sales and Sales Share by Trial Phase (2014-2018)
5.2.2. Global Pharmacovigilance (PV) Revenue and Revenue Share by Trial Phase (2014-2018)
5.3. Pre-clinical
5.3.1. Global Pre-clinical Sales and Growth Rate (2014-2018)
5.4. Phase I
5.4.1. Global Phase I Sales and Growth Rate (2014-2018)
5.5. Phase II
5.5.1. Global Phase II Sales and Growth Rate (2014-2018)
5.6. Phase III
5.6.1. Global Phase III Sales and Growth Rate (2014-2018)
5.7. Phase IV
5.7.1. Global Phase IV Sales and Growth Rate (2014-2018)
6. Pharmacovigilance (PV) Market, By Service Provider
6.1. Introduction
6.2. Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Service Provider (2014-2018)
6.2.1. Global Pharmacovigilance (PV) Sales and Sales Share by Service Provider (2014-2018)
6.2.2. Global Pharmacovigilance (PV) Revenue and Revenue Share by Service Provider (2014-2018)
6.3. In-house
6.3.1. Global Under In-house Sales and Growth Rate (2014-2018)
6.4. Contract Outsourcing
6.4.1. Global Contract Outsourcing Sales and Growth Rate (2014-2018)
7. Pharmacovigilance (PV) Market, By Type
7.1. Introduction
7.2. Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Type (2014-2018)
7.2.1. Global Pharmacovigilance (PV) Sales and Sales Share by Type (2014-2018)
7.2.2. Global Pharmacovigilance (PV) Revenue and Revenue Share by Type (2014-2018)
7.3. Spontaneous Reporting
7.3.1. Global Spontaneous Reporting Sales and Growth Rate (2014-2018)
7.4. Intensified ADR Reporting
7.4.1. Global Intensified ADR Reporting Sales and Growth Rate (2014-2018)
7.5. Targeted Spontaneous Reporting
7.5.1. Global Targeted Spontaneous Reporting Sales and Growth Rate (2014-2018)
7.6. Cohort Event Monitoring
7.6.1. Global Cohort Event Monitoring Sales and Growth Rate (2014-2018)
7.7. EHR Mining
7.7.1. Global EHR Mining Sales and Growth Rate (2014-2018)
8. Pharmacovigilance (PV) Market, By End User
8.1. Introduction
8.2. Global Pharmacovigilance (PV) Sales, Revenue and Market Share by End User (2014-2018)
8.2.1. Global Pharmacovigilance (PV) Sales and Sales Share by End User (2014-2018)
8.2.2. Global Pharmacovigilance (PV) Revenue and Revenue Share by End User (2014-2018)
8.3. Hospitals
8.3.1. Global Hospital Pharmacies Sales and Growth Rate (2014-2018)
8.4. Research Organizations
8.4.1. Global Research Organizations Sales and Growth Rate (2014-2018)
8.5. Industrial
8.5.1. Global Industrial Sales and Growth Rate (2014-2018)
9. Pharmacovigilance (PV) Market, By Region
9.1. Introduction
9.2. Global Pharmacovigilance (PV) Sales, Revenue and Market Share by Regions
9.2.1. Global Pharmacovigilance (PV) Sales by Regions (2014-2018)
9.2.2. Global Pharmacovigilance (PV) Revenue by Regions (2014-2018)
9.3. North America Pharmacovigilance (PV) by Countries
9.3.1. North America Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.3.2. North America Pharmacovigilance (PV) Revenue and Growth Rate (2014-2018)
9.3.3. North America Pharmacovigilance (PV) Sales by Countries (2014-2018)
9.3.4. North America Pharmacovigilance (PV) Revenue (Million USD) by Countries (2014-2018)
9.3.5. U.S.
9.3.5.1. United States Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.3.5.2. United States Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.3.6. Canada
9.3.6.1. Canada Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.3.6.2. Canada Pharmacovigilance (PV) Sales (Millions USD) and Growth Rate (2014-2018)
9.3.7. Mexico
9.3.7.1. Mexico Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.3.7.2. Mexico Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4. Europe Pharmacovigilance (PV) by Countries
9.4.1. Europe Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.2. Europe Pharmacovigilance (PV) Revenue and Growth Rate (2014-2018)
9.4.3. Europe Pharmacovigilance (PV) Sales by Countries (2014-2018)
9.4.4. Europe Pharmacovigilance (PV) Revenue (Million USD) by Countries (2014-2018)
9.4.5. Germany
9.4.5.1. Germany Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.5.2. Germany Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4.6. UK
9.4.6.1. UK Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.6.2. UK Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4.7. France
9.4.7.1. France Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.7.2. France Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4.8. Russia
9.4.8.1. Russia Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.8.2. Russia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4.9. Italy
9.4.9.1. Italy Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.9.2. Italy Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.4.10. Rest of Europe
9.4.10.1. Rest of Europe Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.4.10.2. Rest of Europe Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5. Asia-Pacific
9.5.1. Asia-Pacific Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.2. Asia-Pacific Pharmacovigilance (PV) Revenue and Growth Rate (2014-2018)
9.5.3. Asia-Pacific Pharmacovigilance (PV) Sales by Countries (2014-2018)
9.5.4. Asia-Pacific Pharmacovigilance (PV) Revenue (Million USD) by Countries (2014-2018)
9.5.5. China
9.5.5.1. China Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.5.2. China Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5.6. Japan
9.5.6.1. Japan Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.6.2. Japan Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5.6.3.
9.5.7. Korea
9.5.7.1. Korea Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.7.2. Korea Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5.8. India
9.5.8.1. India Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.8.2. India Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5.9. Southeast Asia
9.5.9.1. Southeast Asia Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.9.2. Southeast Asia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.5.10. Rest of Asia-Pacific
9.5.10.1. Rest of Asia-Pacific Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.5.10.2. Rest of Asia-Pacific Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.6. South America
9.6.1. South America Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.6.2. South America Pharmacovigilance (PV) Revenue and Growth Rate (2014-2018)
9.6.3. South America Pharmacovigilance (PV) Sales by Countries (2014-2018)
9.6.4. South America Pharmacovigilance (PV) Revenue (Million USD) by Countries (2014-2018)
9.6.5. Brazil
9.6.5.1. Brazil Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.6.5.2. Brazil Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.6.6. Argentina
9.6.6.1. Argentina Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.6.6.2. Argentina Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.6.7. Columbia
9.6.7.1. Columbia Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.6.7.2. Columbia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.6.8. Rest of South America
9.6.8.1. Rest of South America Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.6.8.2. Rest of South America Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7. Middle East and Africa
9.7.1. Middle East and Africa Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.2. Middle East and Africa Pharmacovigilance (PV) Revenue and Growth Rate (2014-2018)
9.7.3. Middle East and Africa Pharmacovigilance (PV) Sales by Countries (2014-2018)
9.7.4. Middle East and Africa Pharmacovigilance (PV) Revenue (Million USD) by Countries (2014-2018)
9.7.5. Saudi Arabia
9.7.5.1. Saudi Arabia Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.5.2. Saudi Arabia Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7.6. United Arab Emirates
9.7.6.1. United Arab Emirates Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.6.2. United Arab Emirates Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7.7. Egypt
9.7.7.1. Egypt Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.7.2. Egypt Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7.8. Nigeria
9.7.8.1. Nigeria Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.8.2. Nigeria Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7.9. South Africa
9.7.9.1. South Africa Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.9.2. South Africa Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
9.7.10. Rest of Middle East and Africa
9.7.10.1. Rest of Middle East and Africa Pharmacovigilance (PV) Sales and Growth Rate (2014-2018)
9.7.10.2. Rest of Middle East and Africa Pharmacovigilance (PV) Revenue (Millions USD) and Growth Rate (2014-2018)
10. Company Profiles
10.1. Accenture
10.1.1. Business Overview
10.1.2. Product Portfolio
10.1.3. Strategic Developments
10.1.4. Sales, Revenue and Market Share
10.2. Clinquest Group B.V.
10.2.1. Business Overview
10.2.2. Product Portfolio
10.2.3. Strategic Developments
10.2.4. Sales, Revenue and Market Share
10.3. Cognizant
10.3.1. Business Overview
10.3.2. Product Portfolio
10.3.3. Strategic Developments
10.3.4. Sales, Revenue and Market Share
10.4. Laboratory Corporation of America Holdings
10.4.1. Business Overview
10.4.2. Product Portfolio
10.4.3. Strategic Developments
10.4.4. Sales, Revenue and Market Share
10.5. IBM Corporation
10.5.1. Business Overview
10.5.2. Product Portfolio
10.5.3. Strategic Developments
10.5.4. Sales, Revenue and Market Share
10.6. ArisGlobal
10.6.1. Business Overview
10.6.2. Product Portfolio
10.6.3. Strategic Developments
10.6.4. Sales, Revenue and Market Share
10.7. ICON plc
10.7.1. Business Overview
10.7.2. Product Portfolio
10.7.3. Strategic Developments
10.7.4. Sales, Revenue and Market Share
10.8. Capgemini
10.8.1. Business Overview
10.8.2. Product Portfolio
10.8.3. Strategic Developments
10.8.4. Sales, Revenue and Market Share
10.9. ITClinical
10.9.1. Business Overview
10.9.2. Product Portfolio
10.9.3. Strategic Developments
10.9.4. Sales, Revenue and Market Share
10.10.iMEDGlobal
10.10.1. Business Overview
10.10.2. Product Portfolio
10.10.3. Strategic Developments
10.10.4. Sales, Revenue and Market Share
11. Global Pharmacovigilance (PV) Market Competition, by Manufacturer
11.1. Global Pharmacovigilance (PV) Sales and Market Share by Manufacturer (2016-2017)
11.2. Global Pharmacovigilance (PV) Revenue and Market Share by Manufacturer (2016-2017)
11.3. Global Pharmacovigilance (PV) Price by Manufacturer (2016-2017)
11.4. Top 5 Pharmacovigilance (PV) Manufacturer Market Share
11.5. Market Competition Trend
12. Pharmacovigilance (PV) Market Forecast (2018-2023)
12.1. Global Pharmacovigilance (PV) Sales, Revenue (Millions USD) and Growth Rate (2018-2023)
12.2. Pharmacovigilance (PV) Market Forecast by Regions (2018-2023)
12.2.1. North America Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.1.1. United States Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.1.2. Canada Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.1.3. Mexico Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2. Europe Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2.1. Germany Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2.2. United Kingdom Pharmacovigilance (PV)s Market Forecast (2018-2023)
12.2.2.3. France Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2.4. Russia Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2.5. Italy Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.2.6. Rest of the Europe Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3. Asia-Pacific Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.1. China Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.2. Japan Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.3. Korea Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.4. India Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.5. Southeast Asia Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.3.6. Rest of Asia-Pacific Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.4. South America Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.4.1. Brazil Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.4.2. Argentina Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.4.3. Columbia Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.4.4. Rest of South America Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5. Middle East and Africa Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.1. Saudi Arabia Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.2. UAE Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.3. Egypt Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.4. Nigeria Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.5. South Africa Pharmacovigilance (PV) Market Forecast (2018-2023)
12.2.5.6. Rest of MEA Pharmacovigilance (PV) Market Forecast (2018-2023)
12.3. Pharmacovigilance (PV) Market Forecast by Trial Phase (2018-2023)
12.3.1. Global Pharmacovigilance (PV) Sales Forecast by Trial Phase (2018-2023)
12.3.2. Global Pharmacovigilance (PV) Sales Market Share Forecast by Trial Phase (2018-2023)
12.4. Pharmacovigilance (PV) Market Forecast by Service Provider (2018-2023)
12.4.1. Global Pharmacovigilance (PV) Sales Forecast by Service Provider (2018-2023)
12.4.2. Global Pharmacovigilance (PV) Sales Market Share Forecast by Service Provider (2018-2023)
12.5. Pharmacovigilance (PV) Market Forecast by Type (2018-2023)
12.5.1. Global Pharmacovigilance (PV) Sales Forecast by Type (2018-2023)
12.5.2. Global Pharmacovigilance (PV) Sales Market Share Forecast by Type (2018-2023)
12.6. Pharmacovigilance (PV) Market Forecast by End User (2018-2023)
12.6.1. Global Pharmacovigilance (PV) Sales Forecast by End User (2018-2023)
12.6.2. Global Pharmacovigilance (PV) Sales Market Share Forecast by End User (2018-2023)


Table of Figures

*You can glance through the list of Tables and Figures when you view the sample copy of Pharmacovigilance (PV) Market.

Request Sample

* mark fields are compulsory